Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Physicians to Increase Zytiga Use in Chemo-Naive Prostate Cancer

Jun 26, 2012

Kantar Health Survey Shows Oncologists Will Double Use of Zytiga in Pre-Chemotherapy Setting for Castrate-Resistant Prostate Cancer Patients Following ASCO® Presentation

NEW YORK, June 26, 2012—Physicians said they would use Zytiga® (abiraterone acetate, Janssen) in more than half of their castrate-resistant prostate cancer (CRPC) patients who are asymptomatic or minimally symptomatic in the pre-chemotherapy setting, according to a survey conducted by Kantar Health, a leading healthcare-focused global consultancy and marketing insights company.

Kantar Health conducted a brief survey with US oncologists before and after the recent meeting of the American Society of Clinical Oncology (ASCO) to determine how the presentation of clinical data at the meeting would affect oncologists’ use of oncology treatments.

In the survey conducted prior to ASCO, physicians said they use Zytiga in 23% of their chemo-naive patients; this off-label use is supported by a Category 2B recommendation by the National Comprehensive Cancer Network®. After presentation of the COU-302 trial results at ASCO, oncologists said they expected their utilization to climb to 53% of patients in this setting, primarily at the expense of Provenge® (sipuleucel-T, Dendreon) and docetaxel.

“Zytiga quickly established itself as standard of care in second-line CRPC following its approval in 2011, but its favorable safety profile and high level of efficacy have prompted a wide desire to move the drug into earlier lines of therapy, specifically prior to chemotherapy,” says Stephanie Hawthorne, Ph.D., Director, Kantar Health. “The results presented as ASCO showed a significant increase in radiographic progression-free survival and a trend to overall survival benefit. Physicians in the session seemed uniformly excited about establishing Zytiga as a new standard of care in the chemotherapy-naïve setting.”

Treatment of Asymptomatic or Minimally Symptomatic, Chemotherapy-naïve CRPC (% of Patients)

Reported Use

Expected Use

No therapy/observation (until symptomatic)



Zytiga (abiraterone)



Jevtana (cabazitaxel)






Provenge (sipuleucel-T)



Other regimen




About Kantar Health (

Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.


With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.


Contact Information

For more information on Kantar Health, please contact Paula Paradise, Vice President of Global Marketing, at or +1-484-442-1431.